Pipeline
mRNA Based Therapy
Approved
Clinical
Research & Development
Description
Scarless-101 is a novel ex vivo treatment that modifies a patient’s own hematopoietic stem cells using the CRISPR/Cas9 gene-editing technology. By enabling the creation of fetal hemoglobin in red blood cells, this autologous treatment presents a promising means of treating specific genetic problems. Human hematopoietic stem cells are currently being used to produce Scarless-101, a biosimilar gene therapy. By late 2025 or early 2026, the therapy is expected to begin Phase 1 clinical trials, which would be a major advancement in its path to possible clinical use.
Scarless-101
Sickcle Cell Disease (SCD)
Genome Editing using CRISPR/Cas9
Description
Scarless-102 is a groundbreaking Personalized Cancer Vaccine (PCV) that combines CRISPR/Cas9 gene-editing technology, machine learning, and mRNA-based delivery to revolutionize cancer treatment. This innovative therapy uses advanced machine learning algorithms to analyze a patient’s tumor DNA and predict the most effective neoantigens—unique markers produced by cancer cells due to mutations. Once identified, CRISPR/Cas9 technology is employed to precisely tailor the vaccine, while mRNA technology delivers these neoantigens to the body, instructing the immune system to recognize and attack cancer cells with precision. Scarless-102 represents a highly customized and cutting-edge approach, harnessing the power of gene editing, artificial intelligence, and mRNA to potentially transform the way we treat cancer.
Scarless-102
Personalized Cancer Vaccine using CRISPR/Cas9 technology and machine learning
Title text example
Text after title text example